Celltrion's Jimpentra Sees Threefold Increase in U.S. Prescriptions

Shipments Increase 3.5-Fold, Confirming Rising Demand
Coverage Secured for Over 90% of Insurance Market, Laying the Foundation for Further Expansion

Celltrion's subcutaneous (SC) formulation of infliximab, 'Jimpentra', is showing growth in the U.S. market, with both prescriptions and shipments increasing simultaneously.

Product image of Zympentra. Celltrion

On March 18, Celltrion announced that the number of Jimpentra prescriptions in the U.S. in January of this year increased by approximately three times (213%) compared to the same period last year, reaching a record monthly high. This figure exceeds the entire prescription volume for the first quarter of last year.

Shipments in February also increased by about 3.5 times compared to the same period last year. The company explained that, given the nature of biopharmaceuticals, the expansion of shipments reflects an actual increase in prescription demand.

The scope of insurance coverage has also expanded. Celltrion stated that, through contracts with major U.S. pharmacy benefit managers (PBMs), it has secured coverage for more than 90% of the total insurance market. In January of this year, Evernorth Health Services, a subsidiary of the Cigna Group, listed Jimpentra as a preferred medication in its formulary. The company explained that prescription growth continued through what it calls a '3P strategy' targeting healthcare professionals, insurers, and patients.

A Celltrion official said, "The increase in prescriptions is based on actual demand growth," and added, "We will continue to expand prescriptions in the U.S. market."

This content was produced with the assistance of AI translation services.